Form 4: Syros Pharmaceuticals Director Sells 37,070 Shares

A Syros Pharmaceuticals director, Nancy A. Simonian, sold 37,070 shares of common stock at a weighted average price of $0.2702 on December 2, 2024.

Summary

• Nancy A. Simonian, a director at Syros Pharmaceuticals, sold 37,070 shares of common stock on December 2, 2024.
• The shares were sold at a weighted average price of $0.2702 per share.
• The transactions occurred at prices ranging from $0.2680 to $0.2726 per share.
• Following the transaction, the director still beneficially owns 4,000 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing for an insider stock sale, which is neither positive nor negative in itself. It is a neutral event.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The sale of shares by a director is a common occurrence and does not necessarily indicate a negative outlook for the company.

Stakeholder Impact

• The sale of shares by a director may have a minor impact on investor sentiment, but it is not a significant event in itself.

Key Dates

Keywords

Syros Pharmaceuticals, stock sale, insider trading, Form 4, director, Nancy A. Simonian, equity securities